Repare Therapeutics (NASDAQ:RPTX) Releases Earnings Results, Beats Estimates By $0.10 EPS

Repare Therapeutics (NASDAQ:RPTX) issued its quarterly earnings results on Monday. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.10, Zacks reports. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%.

Repare Therapeutics Stock Performance

RPTX opened at $1.17 on Wednesday. Repare Therapeutics has a 52-week low of $1.06 and a 52-week high of $6.91. The firm has a market cap of $49.74 million, a P/E ratio of -0.59 and a beta of 0.88. The business’s fifty day moving average is $1.26 and its 200-day moving average is $2.45.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on RPTX shares. Lifesci Capital reiterated a “market perform” rating on shares of Repare Therapeutics in a research report on Friday, December 13th. Bloom Burton lowered shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 10th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Repare Therapeutics in a research note on Friday, November 8th. Finally, Stifel Nicolaus dropped their price target on Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, December 13th.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.